Table 1.
Baseline characteristics of studies included in the meta-analysis
| Study | Country | Sample | NAFLD | Control | Method of ANGPTLs measurement | Diagnostic methods | Adjusted factors | Kind of ANGPTLs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | ANGPTLs | Sex (male%) | Age | BMI (kg/m2) | n | ANGPTLs | Sex (male%) | Age | BMI (kg/m2) | |||||||
| Gao et al. 2019 [28] | China | serum | 180 | 275.57 ± 22.38(pg/ml) | 49.40% | 61.25 ± 3.38 | 27.18 ± 2.77 | 72 | 250.23 ± 20.06(pg/ml) | 55.56% | 60.22 ± 4.24 | 23.22 ± 1.46 | Elisa | ultrasound or Liver biopsy | NA | ANGPTL8 |
| Hong et al. 2017 [29] | China | serum | 18 | 765 ± 301(pg/ml) | 38.89% | 56.3 ± 4.9 | 23.4 ± 2.1 | 12 | 742 ± 252(pg/ml) | 50% | 52.2 ± 4.8 | 23.6 ± 1.7 | Elisa | MRI (HCL) | NA | |
| 18 | 1129 ± 351(pg/ml) | 44.44% | 51.9 ± 7.2 | 26.8 ± 2.4 | ||||||||||||
| Lee et al. 2016 [30] | South Korea | serum | 20 | 1197 ± 638(pg/ml) | \ | \ | \ | 18 | 797 ± 506(pg/ml) | \ | \ | 23.4 ± 3.3 | Elisa | ultrasound or CT | age and sex | |
| Loeffelholz et al. 2017 [31] | Germany | plasma | 24 | 1213.9 ± 203.5(pg/ml) | 45.83% | 60 ± 3 | 26.076 ± 4.716 | 16 | 1016.5 ± 191.1(pg/ml) | 31.25% | 54 ± 4 | 23.8 ± 0.9 | Elisa | Liver biopsy | NA | |
| Long et al. 2019 [32] | China | serum | 50 | 1590 ± 820(pg/ml) | 54% | 42.62 ± 5.27 | 25.18 ± 1.54 | 50 | 580 ± 520(pg/ml) | 50% | 42.50 ± 5.38 | 22.76 ± 0.82 | Elisa | ultrasound or Liver biopsy | NA | |
| Yang et al. 2017 [33] | China | serum | 76 | 1320 ± 620(pg/ml) | 56.58% | 39.65 ± 10.58 | 26.87 ± 3.04 | 68 | 900 ± 570(pg/ml) | 55.88% | 40.23 ± 10.72 | 27.09 ± 3.12 | Elisa | ultrasound or Liver biopsy | age and sex | |
| Zhang et al. 2019 [34] | China | serum | 24 | 387 ± 128.64(pg/ml) | 58% | 42.86 ± 9.84 | 22.9 ± 5.64 | 50 | 326 ± 102.62(pg/ml) | 52% | 42.42 ± 9.48 | 23.54 ± 5.84 | \ | ultrasound or Liver biopsy | NA | |
| 58 | 429 ± 140.84(pg/ml) | (n = 100) | (n = 100) | (n = 100) | ||||||||||||
| 18 | 585 ± 214.62(pg/ml) | |||||||||||||||
| Zhang et al. 2021 [35] | China | serum | 347 | 1420 ± 670(pg/ml) | 56.20% | 54.24 ± 5.13 | \ | 120 | 810 ± 390(pg/ml) | 57.50% | 55.02 ± 4.78 | \ | Elisa | ultrasound or Liver biopsy | NA | |
| Zhu et al. 2016 [36] | China | serum | 21 | 1217.42 ± 427.238(pg/ml) | 52.38% | 56.00 ± 14.29 | 26.076 ± 4.716 | 92 | 730.03 ± 431.1(pg/ml) | 65.22% | 53.10 ± 10.06 | 24.4 ± 3 | Elisa | ultrasound or Liver biopsy | age,sex and BMI | |
| Altun et al. 2018 [37] | Turkey | serum | 51 | 303 ± 286(ng/ml) | \ | 37.9 ± 9.9 | 29.2 ± 5.2 | 30 | 369 ± 243(ng/ml) | \ | 34.8 ± 9.5 | 27.8 ± 4.9 | Elisa | ultrasound | NA | ANGPTL4 |
| Yang et al. 2020 [38] | China | serum | 28 | 160 ± 89.86(ng/ml) | \ | 37.52 ± 4.48 | 27.69 ± 3.33 | 47 | 151.5 ± 125.2(ng/ml) | \ | 42.83 ± 4.66 | 23.32 ± 3.4 | Elisa | ultrasound | NA | |
| 24 | 214.7 ± 104.5(ng/ml) | (n = 52) | (n = 52) | |||||||||||||
| Ma et al. 2019 [39] | China | serum | 52 | 410.4 ± 21.17(ng/ml) | 28.85% | 37.52 ± 4.48 | 27.69 ± 3.33 | 51 | 582.9 ± 28.07(ng/ml) | 78.43% | 42.83 ± 4.66 | 23.32 ± 3.4 | Elisa | ultrasound | NA | ANGPTL3 |
| Yilmaz et al. 2009 [40] | Turkey | serum | 40 | 389 ± 110(ng/ml) | 62.50% | 47.9 ± 11.7 | 30.5 ± 4.2 | 14 | 291 ± 78(ng/ml) | 42.86% | 45.9 ± 10.1 | 25.5 ± 2.9 | Elisa | ultrasound or Liver biopsy | age and sex | |
| 8 | 433 ± 70(ng/ml) | 50% | 47.3 ± 10.7 | 28.8 ± 2.7 | ||||||||||||
| 9 | 321 ± 119(ng/ml) | 44.44% | 49.1 ± 11.4 | 29.5 ± 3.7 | ||||||||||||
Rank by the beginning letter of the first authors. Abbreviations: NAFLD Non-alcoholic fatty liver disease, ANGPTLs Angiopoietin-like proteins, BMI Body Mass Index